Literature DB >> 24619868

Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.

Verena Mühlbacher1, Melanie Zenger, Susanne Schnittger, Sandra Weissmann, Franziska Kunze, Alexander Kohlmann, Frauke Bellos, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach.   

Abstract

B lymphoblastic leukemia/lymphoma (ALL) are subdivided by the WHO classification into five subgroups defined by specific translocations and two further subgroups defined by the number of chromosomes. The hypodiploid subgroup is heterogeneous and comprises ALL with a chromosome number of <46. To characterize a specific subset with low hypodiploid karyotype, we performed chromosome banding analysis, FISH, array comparative genomic hybridization, and mutational analyses of FBXW7, NOTCH1, KRAS, NRAS, TP53, and IKZF1 in 29 cases. We observed a nonrandom pattern of chromosome losses, including chromosomes 3, 7, 13, 15, 16, and 17. A deletion encompassing the CDKN2A/B locus was the only recurrent structural abnormality. A duplication of the low hypodiploid karyotype occurred frequently, resulting in a near triploid karyotype based on the definition by merely counting chromosomes but in fact was a very low tetraploid chromosome set. Mutational analyses revealed no mutations in IKZF1, FBXW7, NOTCH1, and KRAS and only one mutation in NRAS. However, we discovered a high frequency of TP53 mutations in 93% (27/29) of cases. In 26/27 cases with TP53 mutation, the second TP53 allele was lost due to monosomy 17. Median overall survival was short (18.5 months), which might be related to the high frequency of TP53 alterations. Therefore, ALL with low hypodiploidy is characterized by a typical pattern of chromosome losses and a remarkably high TP53 mutation frequency. Our data suggest the introduction of a novel WHO entity within the B lymphoblastic leukemia/lymphoma group showing low hypodiploid/very low tetraploid karyotype and concomitant TP53 mutation.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619868     DOI: 10.1002/gcc.22163

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  34 in total

1.  Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis.

Authors:  V Mühlbacher; T Haferlach; W Kern; M Zenger; S Schnittger; C Haferlach
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

2.  Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group.

Authors:  Andrew J Carroll; Mary Shago; Fady M Mikhail; Susana C Raimondi; Betsy A Hirsch; Mignon L Loh; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Kelly W Maloney; Leonard A Mattano; Eric C Larsen; Julie Gastier-Foster; Eileen Stonerock; Denise Ell; Samir Kahwash; Meenakshi Devidas; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Stephen P Hunger; Naomi J Winick; William L Carroll; Kathleen W Rao; Nyla A Heerema
Journal:  Cancer Genet       Date:  2019-07-30

3.  TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.

Authors:  Maoxiang Qian; Xueyuan Cao; Meenakshi Devidas; Wenjian Yang; Cheng Cheng; Yunfeng Dai; Andrew Carroll; Nyla A Heerema; Hui Zhang; Takaya Moriyama; Julie M Gastier-Foster; Heng Xu; Elizabeth Raetz; Eric Larsen; Naomi Winick; W Paul Bowman; Paul L Martin; Elaine R Mardis; Robert Fulton; Gerard Zambetti; Michael Borowitz; Brent Wood; Kim E Nichols; William L Carroll; Ching-Hon Pui; Charles G Mullighan; William E Evans; Stephen P Hunger; Mary V Relling; Mignon L Loh; Jun J Yang
Journal:  J Clin Oncol       Date:  2018-01-04       Impact factor: 44.544

Review 4.  Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui
Journal:  Front Med       Date:  2014-12-15       Impact factor: 4.592

5.  2016 Revision to the WHO classification of acute lymphoblastic leukemia.

Authors:  Shuai Wang; Guangsheng He
Journal:  J Transl Int Med       Date:  2016-12-30

6.  Does TP53 guard ALL genomes?

Authors:  Anthony V Moorman
Journal:  Blood       Date:  2014-07-10       Impact factor: 22.113

7.  Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.

Authors:  Silvia Salmoiraghi; Marie Lorena Guinea Montalvo; Greta Ubiali; Manuela Tosi; Barbara Peruta; Pamela Zanghi; Elena Oldani; Cristina Boschini; Alexander Kohlmann; Silvia Bungaro; Tamara Intermesoli; Elisabetta Terruzzi; Emanuele Angelucci; Irene Cavattoni; Fabio Ciceri; Renato Bassan; Alessandro Rambaldi; Orietta Spinelli
Journal:  Haematologica       Date:  2016-03-18       Impact factor: 9.941

Review 8.  Genomics in acute lymphoblastic leukaemia: insights and treatment implications.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Nat Rev Clin Oncol       Date:  2015-03-17       Impact factor: 66.675

9.  Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Authors:  Seong Lin Khaw; Santi Suryani; Kathryn Evans; Jennifer Richmond; Alissa Robbins; Raushan T Kurmasheva; Catherine A Billups; Stephen W Erickson; Yuelong Guo; Peter J Houghton; Malcolm A Smith; Hernan Carol; Andrew W Roberts; David C S Huang; Richard B Lock
Journal:  Blood       Date:  2016-06-24       Impact factor: 22.113

Review 10.  Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.

Authors:  Lynda M Vrooman; Lewis B Silverman
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.